RSS Newsfeeds

See all RSS Newsfeeds

Apr 28, 2017 9:35 AM ET

Archived: -Biologics Market to Reach $399 Billion by 2025 – Analysis By Source, Products, Disease Category, Manufacturing & Segment

iCrowdNewswire - Apr 28, 2017

M2 PRESSWIRE-April 28, 2017-Biologics Market to Reach $399 Billion by 2025 – Analysis By Source, Products, Disease Category, Manufacturing & Segment


Dublin – Research and Markets has announced the addition of the “Biologics Market, 2014-2025” report to their offering.

The global biologics market is anticipated to reach USD 399.5 billion by 2025. Introduction of targeted therapies coupled with rising adoption of patient centric personalized medicine anticipated to fuel demand. Ever-increasing understanding of the cell physiology and stress, as well as the factors involved in protein production and heterologous gene expression have empowered the use of different living factories.

These living factories are the prokaryotic and eukaryotic cells. Enhancement of drug functionality through achieving successful protein folding and post-translational modifications is supportive for projected progress rate.

Moreover, rising adoption of biopharmaceuticals over chemically synthesized molecules is expected to propel revenue generation significantly. In addition to this, presence of several metabolic disorders that can be treated through the use of biologics is attributive to influence demand.

Combination of advanced bioengineering technologies for biopharmaceutical production is expected to boost progress in pharmaceutical industry. With recent advances in automation, the selection process can be done through high throughput screening (HTS) system for selection of viable clones.

Aforementioned method enables robust production of biopharmaceutical products by obtaining high-producing cell line. Advances with respect to upstream and downstream processing would directly translate into the growth in revenue for this market at a larger level.

However, development of biosimilars is expected to restrain the biologics year on year growth to certain extent. Although, the regulatory approval pathway for these products is not framed yet some drug manufacturers are opting to invest in the development of biobetters.

Companies Mentioned

– Samsung BioLogics
– Amgen
– Novo Nordisk A/S
– AbbVie Inc.
– Sanofi
– Johnson & Johnson Services, Inc
– Pfizer Inc.
– Merck & Co., Inc.
– GSK group of companies
– Celltrion
– Precision Biologics, Inc.
– Merck KGaA
– Eli Lilly and Company
– Novartis AG
– Bayer AG
– F. Hoffmann-La Roche Ltd
– AstraZeneca

Key Topics Covered:

1 Research Methodology

2 Executive Summary

3 Biologics Market Variables, Trends & Scope

4 Biologics Market: Source Estimates & Trend Analysis

5 Biologics Market: Product Estimates & Trend Analysis

6 Biologics Market: Manufacturing Estimates & Trend Analysis

7 Biologics Market: Disease Category Estimates & Trend Analysis

8 Biologics Market: Regional Estimates & Trend Analysis, by Source, Product, Manufacturing, & Disease Category

9 Competitive Landscape

For more information about this report visit http://www.researchandmarkets.com/research/bkk3v6/biologics_market

Contact Information:

Research and Markets,
Laura Wood,
Senior Manager.
Fax from USA: 646-607-1907
Fax from rest of the world: +353-1-481-1716
Related Topics: Biopharmaceuticals (http://www.researchandmarkets.com/categories.asp?cat_id=583&campaign_id=bkk3v6)

((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.m2.com on the world wide web. Inquiries to info@m2.com)).

Via iCrowdNewswire
Tags: , Wire, M2 Presswire
View Related News >